REVERSAL OF HIGH BREAST CANCER RISK IN MAMMALS EXPOSED TO ESTROGENIC CHEMICALS IN UTERO BY ADULT EXPOSURE TO HDAC AND DNMT INHIBITORS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 5, 2013
app pub date -
Apr 5, 2013
filing date -
Apr 6, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Methods of reducing breast cancer risk in an individual exposed in utero to an elevated estrogenic environment, where the individuals are identified by obtaining a measurement of at least one of: (a) DNMT1 expression; (b) methylation of normally unmethylated CpG islands of tumor suppressor genes; and (c) polycomb target genes, in cells obtained from the individual and comparing the measurement to a statistical level of a population not exposed in utero to an elevated estrogenic environment. Methods of reducing breast cancer risk in such an individual can be reduced by administering at least one DNA methyltransferase (DNMT) and/or histone deacetylase (HDAC) inhibitor. The administration of these inhibitors may be part of a treatment regime which may include the administration of at least one anti-cancer agent.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully